Acquisition Announced Sponsor buyer

Gilead Sciences acquisition of Arcellx

US$7.8bn equity value

Announced 23 Feb 2026 · NASDAQ: ACLX · US$115.00 cash and scrip per share · 68% premium

Advisers

Arcellx

Target

Financial adviser
Fairness opinion

Parent

Acquirer

Financial adviser
Legal adviser
The information agent for the Offer
Target
Arcellx
Acquirer
Parent (Gilead Sciences)
Sponsor
Gilead Sciences
Target based in
United States
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Cell Therapy, Oncology

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.